RC48 Combined with PD-1 Inhibitors: Clinical Outcomes for Metastatic Urothelial Carcinoma

132 patient records from a multicenter real-world study evaluating the combination therapy of disitamab vedotin (RC48) and PD-1 inhibitors for locally advanced or metastatic urothelial carcinoma. The dataset includes clinical-pathological characteristics, treatment regimens, efficacy outcomes, and safety assessments collected between June 2022 and March 2024. It was authored by Xin Chang Zou and shared under a CC-BY-4.0 license.

Use Cases

• Analyze progression-free survival (PFS) and overall survival (OS) outcomes based on Kaplan-Meier survival curves mentioned in the description
• Evaluate the impact of comorbidities like hypertension and diabetes on treatment efficacy based on subgroup analyses described
• Assess the safety profile of the combination therapy based on recorded treatment-related adverse events (TRAEs)
• Model prognostic factors for urothelial carcinoma based on clinical-pathological characteristics collected
• Compare objective response rate (ORR) and disease control rate (DCR) across different patient subpopulations

Strengths

• Includes 132 patient records from six treatment centers, providing a multicenter perspective
• Reports specific efficacy metrics: ORR of 71.21% and DCR of 88.64% with confidence intervals
• Provides detailed safety data, listing common adverse events and a grade 3 incidence rate of 13.64%
• Contains a median PFS of 21 months with a defined 95% confidence interval

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown for the underlying data tables, which may limit suitability assessment
• Data may reflect temporal bias inherent to the specific collection period from June 2022 to March 2024

Provenance

Source

Xin Chang Zou

Collection Method

Retrospective analysis of electronic medical records from six treatment centers

Time Range

June 2022 to March 2024

Freshness

Last updated 2026-04-29 05:54:18; freshness should be verified